Burzynski Research Institute, Inc. (BZYR)
USD 0.05
(-1.63%)
USD 0.05
(-1.63%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 1.33 Million USD | 45.74% |
| 2023 | 916.29 Thousand USD | -6.18% |
| 2022 | 976.65 Thousand USD | -24.97% |
| 2021 | 1.3 Million USD | -20.38% |
| 2020 | 1.63 Million USD | -0.17% |
| 2019 | 1.63 Million USD | 1.53% |
| 2018 | 1.61 Million USD | 7.2% |
| 2017 | 1.5 Million USD | -24.96% |
| 2016 | 2 Million USD | -30.67% |
| 2015 | 2.89 Million USD | -32.3% |
| 2014 | 4.27 Million USD | -34.27% |
| 2013 | 6.49 Million USD | -9.2% |
| 2012 | 7.15 Million USD | 42.26% |
| 2011 | 5.03 Million USD | 4.15% |
| 2010 | 4.83 Million USD | -5.78% |
| 2009 | 5.12 Million USD | 13.38% |
| 2008 | 4.52 Million USD | 5.1% |
| 2007 | 4.3 Million USD | -7.56% |
| 2006 | 4.65 Million USD | -6.27% |
| 2005 | 4.96 Million USD | 13.26% |
| 2004 | 4.38 Million USD | -0.81% |
| 2003 | 4.42 Million USD | -14.65% |
| 2002 | 5.17 Million USD | 12.78% |
| 2001 | 4.59 Million USD | 4.0% |
| 2000 | 4.41 Million USD | -11.97% |
| 1999 | 5.01 Million USD | -29.61% |
| 1998 | 7.12 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 FY | 1.33 Million USD | 45.74% |
| 2024 Q4 | 362.9 Thousand USD | -16.19% |
| 2024 Q3 | 433.01 Thousand USD | 71.76% |
| 2024 Q2 | 252.1 Thousand USD | -12.28% |
| 2024 Q1 | 287.4 Thousand USD | 33.06% |
| 2023 Q2 | 215.91 Thousand USD | -6.83% |
| 2023 FY | 916.29 Thousand USD | -6.18% |
| 2023 Q4 | 215.99 Thousand USD | -14.5% |
| 2023 Q3 | 252.63 Thousand USD | 17.01% |
| 2023 Q1 | 231.73 Thousand USD | 35.61% |
| 2022 Q3 | 264.77 Thousand USD | 17.83% |
| 2022 Q1 | 316.28 Thousand USD | 26.04% |
| 2022 FY | 976.65 Thousand USD | -24.97% |
| 2022 Q4 | 170.87 Thousand USD | -35.46% |
| 2022 Q2 | 224.71 Thousand USD | -28.95% |
| 2021 Q3 | 264.32 Thousand USD | -19.55% |
| 2021 Q1 | 457.97 Thousand USD | 60.83% |
| 2021 Q4 | 250.93 Thousand USD | -5.07% |
| 2021 FY | 1.3 Million USD | -20.38% |
| 2021 Q2 | 328.54 Thousand USD | -28.26% |
| 2020 Q1 | 468.31 Thousand USD | 38.21% |
| 2020 Q4 | 284.75 Thousand USD | -39.63% |
| 2020 FY | 1.63 Million USD | -0.17% |
| 2020 Q2 | 410.22 Thousand USD | -12.4% |
| 2020 Q3 | 471.69 Thousand USD | 14.99% |
| 2019 Q4 | 338.83 Thousand USD | -22.93% |
| 2019 Q3 | 439.63 Thousand USD | -2.23% |
| 2019 FY | 1.63 Million USD | 1.53% |
| 2019 Q1 | 409.57 Thousand USD | 26.41% |
| 2019 Q2 | 449.67 Thousand USD | 9.79% |
| 2018 Q2 | 425.74 Thousand USD | -7.89% |
| 2018 FY | 1.61 Million USD | 7.2% |
| 2018 Q1 | 462.21 Thousand USD | 32.13% |
| 2018 Q3 | 401.12 Thousand USD | -5.78% |
| 2018 Q4 | 324.01 Thousand USD | -19.22% |
| 2017 FY | 1.5 Million USD | -24.96% |
| 2017 Q1 | 369.95 Thousand USD | -9.79% |
| 2017 Q3 | 383.13 Thousand USD | -4.65% |
| 2017 Q4 | 349.81 Thousand USD | -8.7% |
| 2017 Q2 | 401.81 Thousand USD | 8.61% |
| 2016 Q3 | 460.19 Thousand USD | -9.82% |
| 2016 Q1 | 624.52 Thousand USD | 1.24% |
| 2016 Q4 | 410.08 Thousand USD | -10.89% |
| 2016 FY | 2 Million USD | -30.67% |
| 2016 Q2 | 510.3 Thousand USD | -18.29% |
| 2015 FY | 2.89 Million USD | -32.3% |
| 2015 Q1 | 840.88 Thousand USD | 1.88% |
| 2015 Q4 | 616.88 Thousand USD | -12.83% |
| 2015 Q3 | 707.64 Thousand USD | -2.62% |
| 2015 Q2 | 726.69 Thousand USD | -13.58% |
| 2014 Q4 | 825.36 Thousand USD | -16.03% |
| 2014 Q2 | 1.1 Million USD | -18.46% |
| 2014 Q3 | 982.86 Thousand USD | -11.17% |
| 2014 FY | 4.27 Million USD | -34.27% |
| 2014 Q1 | 1.35 Million USD | -9.23% |
| 2013 Q4 | 1.49 Million USD | -2.27% |
| 2013 Q1 | 1.68 Million USD | -17.31% |
| 2013 Q2 | 1.79 Million USD | 6.79% |
| 2013 FY | 6.49 Million USD | -9.2% |
| 2013 Q3 | 1.52 Million USD | -14.74% |
| 2012 Q2 | 1.78 Million USD | 18.93% |
| 2012 FY | 7.15 Million USD | 42.26% |
| 2012 Q3 | 1.83 Million USD | 3.08% |
| 2012 Q4 | 2.03 Million USD | 10.42% |
| 2012 Q1 | 1.5 Million USD | 20.88% |
| 2011 Q4 | 1.24 Million USD | 2.65% |
| 2011 Q3 | 1.2 Million USD | 0.43% |
| 2011 Q1 | 1.37 Million USD | 5.13% |
| 2011 Q2 | 1.2 Million USD | -12.42% |
| 2011 FY | 5.03 Million USD | 4.15% |
| 2010 Q4 | 1.3 Million USD | 8.21% |
| 2010 Q2 | 1.19 Million USD | 6.78% |
| 2010 FY | 4.83 Million USD | -5.78% |
| 2010 Q1 | 1.11 Million USD | -7.97% |
| 2010 Q3 | 1.2 Million USD | 1.19% |
| 2009 Q3 | 1.34 Million USD | 4.01% |
| 2009 FY | 5.12 Million USD | 13.38% |
| 2009 Q1 | 1.28 Million USD | 0.27% |
| 2009 Q2 | 1.29 Million USD | 0.64% |
| 2009 Q4 | 1.21 Million USD | -9.42% |
| 2008 FY | 4.52 Million USD | 5.1% |
| 2008 Q4 | 1.27 Million USD | 24.22% |
| 2008 Q3 | 1.02 Million USD | -10.73% |
| 2008 Q1 | 1.06 Million USD | 2.0% |
| 2008 Q2 | 1.15 Million USD | 8.67% |
| 2007 Q1 | 1.15 Million USD | 8.11% |
| 2007 Q4 | 1.04 Million USD | 8.48% |
| 2007 Q3 | 958.92 Thousand USD | -16.33% |
| 2007 Q2 | 1.14 Million USD | -0.98% |
| 2007 FY | 4.3 Million USD | -7.56% |
| 2006 Q1 | 1.18 Million USD | -8.93% |
| 2006 Q2 | 1.3 Million USD | 10.51% |
| 2006 Q3 | 1.09 Million USD | -16.43% |
| 2006 Q4 | 1.07 Million USD | -2.04% |
| 2006 FY | 4.65 Million USD | -6.27% |
| 2005 Q2 | 1.21 Million USD | -6.25% |
| 2005 Q4 | 1.29 Million USD | 11.89% |
| 2005 Q3 | 1.16 Million USD | -4.2% |
| 2005 Q1 | 1.29 Million USD | 0.12% |
| 2005 FY | 4.96 Million USD | 13.26% |
| 2004 FY | 4.38 Million USD | -0.81% |
| 2004 Q1 | 1.06 Million USD | -12.7% |
| 2004 Q2 | 1.13 Million USD | 7.06% |
| 2004 Q3 | 888.16 Thousand USD | -22.09% |
| 2004 Q4 | 1.29 Million USD | 45.39% |
| 2003 Q3 | 1.1 Million USD | 9.21% |
| 2003 FY | 4.42 Million USD | -14.65% |
| 2003 Q1 | 1.07 Million USD | -12.01% |
| 2003 Q2 | 1.01 Million USD | -5.72% |
| 2003 Q4 | 1.21 Million USD | 10.02% |
| 2002 FY | 5.17 Million USD | 12.78% |
| 2002 Q4 | 1.22 Million USD | 0.31% |
| 2002 Q1 | 1.41 Million USD | 28.46% |
| 2002 Q2 | 1.31 Million USD | -7.08% |
| 2002 Q3 | 1.21 Million USD | -7.42% |
| 2001 Q4 | 1.1 Million USD | -8.94% |
| 2001 Q2 | 1.19 Million USD | 10.23% |
| 2001 Q1 | 1.08 Million USD | 4.22% |
| 2001 FY | 4.59 Million USD | 4.0% |
| 2001 Q3 | 1.21 Million USD | 1.55% |
| 2000 Q4 | 1.03 Million USD | 2.83% |
| 2000 FY | 4.41 Million USD | -11.97% |
| 2000 Q1 | 1.29 Million USD | 0.0% |
| 2000 Q2 | 1.07 Million USD | -17.25% |
| 2000 Q3 | 1.01 Million USD | -5.69% |
| 1999 FY | 5.01 Million USD | -29.61% |
| 1998 FY | 7.12 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Arch Therapeutics, Inc. | 5.04 Million USD | 73.514% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 95.481% |
| Nascent Biotech, Inc. | 2.22 Million USD | 40.112% |
| Rebus Holdings, Inc. | 664 Thousand USD | -101.119% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 96.415% |
| Qrons Inc. | 643.67 Thousand USD | -107.469% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -242.8% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 97.675% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -221.42% |
| Skye Bioscience, Inc. | 13.54 Million USD | 90.143% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 98.461% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 72.846% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -410.24% |
| SQZ Biotechnologies Company | 85.61 Million USD | 98.44% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 54.207% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 11.084% |
| Mesoblast Limited | 5.9 Million USD | 77.373% |
| Marizyme, Inc. | 19.23 Million USD | 93.059% |
| Genus plc | 147.7 Million USD | 99.096% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 84.789% |
| Pharming Group N.V. | 225.49 Million USD | 99.408% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 34.816% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 0.456% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 83.986% |
| ContraFect Corporation | 56.88 Million USD | 97.653% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 69.709% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 9.692% |
| IMV Inc. | 37.7 Million USD | 96.459% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 52.141% |
| MultiCell Technologies, Inc. | 567.42 USD | -235251.415% |
| ONE Bio Corp. | 6.44 Million USD | 79.276% |
| Accustem Sciences Inc. | 3.74 Million USD | 64.354% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 98.446% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -151.039% |
| Q BioMed Inc. | 3.43 Million USD | 61.141% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 94.597% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 49.175% |
| Biomind Labs Inc. | 994.18 Thousand USD | -34.325% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 98.656% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 24.109% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 80.122% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 28.371% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 5441.724% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 91.659% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 27.228% |
| GB Sciences, Inc. | 1.42 Million USD | 5.989% |
| Alpha Cognition Inc. | 9.7 Million USD | 86.241% |
| HST Global, Inc. | 140.9 Thousand USD | -847.739% |
| CSL Limited | 3.44 Billion USD | 99.961% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -18.714% |
| Halberd Corporation | 74.84 Thousand USD | -1684.334% |
| Enzolytics Inc. | 2.17 Million USD | 38.728% |
| Agentix Corp. | 1.37 Million USD | 2.648% |
| Resverlogix Corp. | 12.71 Million USD | 89.495% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 63.42% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.913% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -27.915% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 44.471% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 15.445% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 60.78% |
| AVAX Technologies, Inc. | 7.31 Million USD | 81.732% |
| Zenith Capital Corp. | 8.94 Million USD | 85.067% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.838% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -7565.639% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 45.611% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -678.636% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 30.479% |
| Kadimastem Ltd | 2.41 Million USD | 44.591% |
| Helix BioMedix, Inc. | 1.97 Million USD | 32.282% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 87.711% |
| BioStem Technologies, Inc. | 22.97 Million USD | 94.187% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -635.835% |
| LadRx Corporation | 3.81 Million USD | 64.966% |
| Cell Source, Inc. | 4.32 Million USD | 69.125% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -44.604% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -44.604% |
| NovAccess Global Inc. | 2.46 Million USD | 45.863% |
| Affymax, Inc. | 39.38 Million USD | 96.609% |
| Itoco Inc. | 919.14 Thousand USD | -45.291% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 68.492% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -19.341% |
| Mobile Lads Corp. | 554.54 Thousand USD | -140.815% |
| CytoDyn Inc. | 18.05 Million USD | 92.605% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -5205.856% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -506.799% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 5.942% |
| SYBLEU INC | 160.87 Thousand USD | -730.1% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 26.476% |
| International Stem Cell Corporation | 5.27 Million USD | 74.665% |
| Bioxytran, Inc. | 3.82 Million USD | 65.042% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -2436.817% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -6464.573% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 96.318% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 17.464% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -81.485% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 57.074% |
| Neutra Corp. | 243.82 Thousand USD | -447.71% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 92.35% |
| PureTech Health plc | 144.59 Million USD | 99.076% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 93.482% |
| IXICO plc | 4.7 Million USD | 71.629% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 84.819% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 98.866% |
| CSL Limited | 3.89 Billion USD | 99.966% |
| Cellectis S.A. | 97.32 Million USD | 98.628% |